Infection

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant

Retrieved on: 
Wednesday, July 6, 2022 - 7:00am

The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.

Key Points: 
  • The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.
  • About 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene, making it the most common genetic ALS variant.
  • DZNE developed an experimental vaccine that instructs the immune system to produce antibodies against these harmful poly-GA molecules.
  • Clinical trials for C9orf72 ALS, which is the most common genetic variant of ALS, are expected to commence in 2025.

DGAP-News: Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Retrieved on: 
Wednesday, July 6, 2022 - 7:04am

We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMrieux, to combine our complementary strengths.

Key Points: 
  • We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMrieux, to combine our complementary strengths.
  • We supply the most comprehensive integrated diagnostic solutions to support an appropriate use of antibiotics (antimicrobial stewardship), said Alexandre Mrieux, bioMrieux Chairman and CEO.
  • Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results.
  • bioMrieux has over 55 years of diagnostics expertise with more than 75% of its research and development budget focused on antimicrobial resistance.

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Retrieved on: 
Wednesday, July 6, 2022 - 6:50am

The aspiration is to succeed in the fight against AMR, which is a major public health threat.

Key Points: 
  • The aspiration is to succeed in the fight against AMR, which is a major public health threat.
  • The rise of antibiotic-resistant infections also called antimicrobial resistance, or AMR is indeed a looming global crisis, said Michel Pairet, Head of Boehringer Ingelheims Innovation Unit and Member of the Board of Managing Directors.
  • We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMrieux, to combine our complementary strengths.
  • bioMrieux has over 55 years of diagnostics expertise with more than 75 percent of its research and development budget focused on antimicrobial resistance.

FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma

Retrieved on: 
Wednesday, July 6, 2022 - 6:00am

The FDA is expected to make a decision on approval of this novel cancer immunotherapy by December 29, 2022.

Key Points: 
  • The FDA is expected to make a decision on approval of this novel cancer immunotherapy by December 29, 2022.
  • New therapeutic options are needed for follicular lymphoma, which often relapses after initial therapy and becomes increasingly difficult to treat each time it returns.
  • The GO29781 study [ NCT02500407 ] is a Phase I/II, multicenter, open-label, dose-escalation and expansion study evaluating the safety, efficacy and pharmacokinetics of mosunetuzumab in people with relapsed or refractory B-cell non-Hodgkins lymphoma.
  • Follicular lymphoma (FL) is the most common slow-growing (indolent) form of non-Hodgkins lymphoma, accounting for about one in five cases.

HF Sinclair Corporation Announces Appointment of Rhoman Hardy to Its Board of Directors

Retrieved on: 
Tuesday, July 5, 2022 - 9:15pm

HF Sinclair Corporation (NYSE:DINO) (HF Sinclair) today announced that its Board of Directors (the Board) appointed Rhoman J. Hardy to the Board, effective July 2, 2022.

Key Points: 
  • HF Sinclair Corporation (NYSE:DINO) (HF Sinclair) today announced that its Board of Directors (the Board) appointed Rhoman J. Hardy to the Board, effective July 2, 2022.
  • This appointment increases the size of the Board to twelve directors and increases the number of independent directors on the Board from nine to ten.
  • He brings strong industry experience and expertise to the HF Sinclair Board.
  • We look forward to his contributions to our Board and HF Sinclair, said Franklin Myers, Chairman of the Board.

Finding HIV's Sweet Spot

Retrieved on: 
Tuesday, July 5, 2022 - 8:35pm

SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- HIV researchers have long been trying to identify the specific cells that the virus prefers to infect and hide in. They know that HIV favors a special type of immune cells called memory CD4 T cells. But these cells come in many flavors, and it has been difficult to ascertain exactly what makes one type of memory CD4 T cell more attractive to HIV than another.

Key Points: 
  • Together, the scientists uncovered surprisingly different sugar patterns on different immune cells, and an intriguing interplay between HIV and the sugars coating CD4 Tcells.
  • The work also showcases a new technique for studying individual cells from large populations that could lead to a more detailed picture of cellular diversity.
  • Encouraged by this finding, the scientists next applied CyTOF-Lec to CD4 Tcells that they had first exposed to HIV in the lab.
  • To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impactunsolved diseases.

MetroPlusHealth Promotes Julie Myers, M.D., M.P.H., to Deputy Chief Medical Officer

Retrieved on: 
Tuesday, July 5, 2022 - 3:20pm

NEW YORK, July 5, 2022 /PRNewswire/ -- MetroPlusHealth, New York City's high-quality and affordable health plan, announced the promotion of Julie Myers, M.D., MPH., as the new Deputy Chief Medical Officer (DCMO). Dr. Myers was previously appointed Medical Director of the Plan's Partnership in Care (P.I.C.) Special Needs Plan in February 2020 and assumed her new position as DCMO on June 16, 2022.

Key Points: 
  • Special Needs Plan
    NEW YORK, July 5, 2022 /PRNewswire/ -- MetroPlusHealth, New York City's high-quality and affordable health plan, announced the promotion of Julie Myers, M.D., MPH., as the new Deputy Chief Medical Officer (DCMO).
  • Services," said Sanjiv Shah, M.D., Chief Medical Officer of MetroPlusHealth.
  • Schwartz and Shah, and I am now both honored and energized to serve a greater number of New Yorkers in this new role," said Julie Myers, M.D., M.P.H., Deputy Chief Medical Director of MetroPlusHealth.
  • For more information about MetroPlusHealth plans, benefits, and services, visit www.metroplus.org and join the conversation at facebook.com/metroplushealth and twitter @metroplushealth.

Sandoz Canada expands its generics portfolio with three new products

Retrieved on: 
Tuesday, July 5, 2022 - 1:54pm

During the spring, Sandoz Canada has launched the following three products.

Key Points: 
  • During the spring, Sandoz Canada has launched the following three products.
  • PrSandoz Teriflunomide is the third multiple sclerosis treatment in the companys portfolio, following the launch of Sandoz Fingolimod in November 2019 and Sandoz Dimethyl Fumarate in October 2021.
  • We are very proud of these additions to the Sandoz Canada portfolio, says Michel Robidoux, President and General Manager of Sandoz Canada.
  • Sandoz International GmbH is a world leader in generics and biosimilars and a division of the Swiss multinational Novartis.

Mithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy Campaign

Retrieved on: 
Tuesday, July 5, 2022 - 1:00pm

We thank you, our fellow shareholders, for the overwhelming support you gave these proposals.

Key Points: 
  • We thank you, our fellow shareholders, for the overwhelming support you gave these proposals.
  • Almost two years ago Adagio Therapeutics launched with a clear mission: deploy the worlds most advanced biological discovery technology to make drugs against important viral targets, including SARS-CoV-2.
  • To do so, Adagio aimed to create the leading infectious diseases platform equipped with the worlds best antibody discovery technology.
  • Our successful proxy effort was intended to help advance this mission, and we will continue to monitor developments at Adagio with a view to supporting brisk progress.

Healthy Eating Goes Smart: App Developer Foogal and Autoimmune Disease Expert Dr. Terry Wahls Form Partnership

Retrieved on: 
Tuesday, July 5, 2022 - 1:39pm

LINCOLN, Neb., July 5, 2022 /PRNewswire/ -- Author and leading medical expert in autoimmune disease, Dr. Terry Wahls, has joined forces with Foogal , a digital health software company, to help people take control of their health through proper nutrition and healthy eating.

Key Points: 
  • LINCOLN, Neb., July 5, 2022 /PRNewswire/ -- Author and leading medical expert in autoimmune disease, Dr. Terry Wahls, has joined forces with Foogal , a digital health software company, to help people take control of their health through proper nutrition and healthy eating.
  • Dr. Terry Wahls , Professor of Medicine at the University of Iowa, is best known for her miraculous recovery from Secondary Progressive Multiple Sclerosis.
  • Dr. Wahls will work with Foogal to help the 23.5 million Americans suffering from autoimmune conditions follow her lead and take control of their health.
  • Foogal and Dr. Wahls' collaboration will blend technology and medical expertise to provide a stress-free, easy-to-use roadmap for optimal wellness.